The CD133 has been identified as a marker of neural stem cells in the adult central nervous system as well as of brain CSCs (7, 8, 14) .
Although the biological function of CD133 is not well understood, this molecule currently serves as a useful marker for the isolation of CSCs. The CD133-positive cells could be potential targets for cancer therapy. Therefore, the recent research is attempting to elucidate the nature and role in tumorigenesis of CSCs.
The proliferation and differentiation potential of neural stem cells can be modulated by endogenous and environmental factors (15) . A combination of epidermal growth factor (EGF) and fibroblast growth factor-2 (FGF-2) promotes their proliferation and differentiation (16) (17) (18) .
Vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) are also classified as neurotrophic factors, which play essential roles in the development, maintenance, and regeneration of the central nervous system (19, 20) . Moreover, hepatocyte growth factor (HGF) is present in the developing and mature central nervous system (21) , implying its role in this system. These growth factors and their receptors should also be implicated in glioma tumorigenesis and the acquisition of malignancy (22) (23) (24) . However, it remains unknown which of these growth factors play(s) a pivotal role in the proliferation and differentiation of CSCs.
In the present study, we have established CSC lines from three brain tumor patients and examined the growth factor dependence of these kinase to block CSC self-renewal was also tested.
The tyrosine kinase inhibitors gefitinib (ZD1839, Iressa; AstraZeneca) and AG1478 quite efficiently inhibited EGF-dependent sphere formation.
Gefitinib also significantly decreased the CD133 populations by flow cytometric analysis.
Autophosphorylation of EGFR was inhibited by
gefitinib in a concentration-dependent manner.
Among EGFR downstream signaling molecules (25, 26) , phosphorylation of Akt kinase and extracellular signal-regulated kinase (ERK) 1/2, but not STAT3, was suppressed by gefitinib.
Blockage of both ERK and Akt pathways by selective inhibitors, PD98059 and LY294002, respectively, resulted in considerable inhibition of EGF-dependent sphere formation. These findings indicate that EGF signaling cascade is essential for the maintenance of brain tumor stem cells.
Experimental Procedures
Primary sphere formation-Prior informed consent was obtained from all 3 sample donors.
Our study was approved by the Medical Review
Board of Gifu University. Tumor-sphere cultures were performed as described previously with some modifications in medium containing DMEM-F12 (GIBCO-Invitrogen, La Jolla, CA), penicillin G, streptomycin sulfate, B-27 (GIBCO-Invitrogen), recombinant human FGF-2 (20 ng/ml; R&D Systems, Minneapolis, MN), recombinant human EGF (20 ng/ml; R&D Systems), and leukemia inhibitory factor (1000 U/ml) (6, 7, 11, 12) .
Limiting dilution assay-Sphere cells were dissociated and seeded in 96-well culture plates in 0.2 ml medium (7, 12) . The final cell dilutions ranged from 1 to 1000 cells/well. Cultures were fed 20 μl of medium every 2 days, until day 7.
The percentage of wells not containing spheres for each cell plating density was calculated and plotted against the number of cells per well.
Immunofluorescent staining-

Immunocytochemistry of tumor-spheres and
by on March 1, 2008 www.jbc.org Downloaded from differentiated spheres were performed as described (11, 12 μl/min) of anesthetized NOD-SCID mice using a Hamilton syringe. The injection coordinates were 3 mm to the right of the midline and 2 mm anterior to the coronal suture at a depth of 3 mm.
The mice were sacrificed at 4-14 weeks post-injection depending on the injected cell line (11, 12) .
Histochemical analysis of brain tissues-Tumor
samples were fixed with 4% paraformaldehyde. The number of formed spheres was counted.
Western blotting-Western blot analysis was performed essentially as described previously Statistical analysis-Parametric comparisons used analysis of variance (ANOVA). The ANOVAs were followed by Tukey's honestly significant difference adjustment for multiple comparisons. (Fig. 3B) . The sphere forming effect was observed at a concentration as low as 2.5 ng/ml EGF (Fig. 3C) X02GB by RT-PCR (Fig. 4B) . Considering the fact that these CSC cells could not form tumor-spheres without EGF, these data suggest that sphere formations of brain CSCs are indispensably supported by EGF-EGFR signaling but not by the expression of EGFRvIII.
RESULTS
Isolation of tumorigenic
The strict dependence of our CSCs on EGF-signaling was further evaluated by means of tyrosine kinase inhibitors relatively selective for EGFR kinase, AG1478 (32) and the clinically used gefitinib (Iressa, ZD1839) (27,33) using modified limiting dilution assays (Fig. 5A) . At 0.1 μM, AG1478 effectively inhibited sphere formation of these cell lines. Although gefitinib did not show a significant inhibitory effect at the same concentration, at 1.0 μM it almost completely suppressed the self-renewal of these spheres (Fig. 5B) . Currently, we don't have sound explanation for the observed nearly 10-fold difference in effective concentration between AG1478 and gefitinib. This may be, however, due to the nearly 10-fold difference in reported IC 50 A selective inhibitor of ERK pathway, PD98059 (10 μM) had no effect on EGF-induced sphere formation (Fig. 5D ). LY294002 (10 μM), an inhibitor of PI3K/Akt pathway slightly but not significantly blocked sphere formation. When
CSCs were treated with a combination of PD98059 and LY294002, sphere formation was significantly inhibited. These data also support the notion that EGF signaling plays a key role in CSC sphere formation and self-renewal. Furthermore, colony formations of the CD133-positive cells were suppressed by nearly 90% by the exposure to 10 μM gefitinib (Fig. 6C ).
Effects of EGF and gefitinib
In addition, CSC cells expressing cleaved caspase-3, a marker of apoptotic cell death, increased by 3-4-fold in the presence of 10 μM gefitinib (Fig. 6D) . (Table S1 and S2 in the Supplementary data available). 
